Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China

Background: Hepatitis C virus (HCV) genotype 1 is the most prevalent HCV infection in China. Sofosbuvir-based direct antiviral agent (DAA) regimens are the current mainstays of treatment. Sofosbuvir/velpatasvir (SOF/VEL) and sofosbuvir/ledipasvir (SOF/LDV) regimens became reimbursable in China in 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Hui Jun, Cao, Jing, Shi, Hui, Naidoo, Nasheen, Semba, Sherehe, Wang, Pei, Fan, Yi Fan, Zhu, Shui Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695807/
https://www.ncbi.nlm.nih.gov/pubmed/34957030
http://dx.doi.org/10.3389/fpubh.2021.779215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695807/
https://www.ncbi.nlm.nih.gov/pubmed/34957030
http://dx.doi.org/10.3389/fpubh.2021.779215

Ejemplares similares